Is Intrarosa a Non-Estrogen Treatment?
Yes, Intrarosa (prasterone) is classified as a non-estrogen treatment for moderate to severe dyspareunia due to menopausal vulvar and vaginal atrophy (VVA). It is a synthetic form of dehydroepiandrosterone (DHEA), a naturally occurring steroid hormone precursor produced by the adrenal glands.[1] Unlike estrogen therapies such as vaginal estradiol creams or rings, Intrarosa does not contain or deliver estrogen directly.
How Does Intrarosa Work Without Estrogen?
Intrarosa is inserted vaginally as a daily ovule. Once inside, DHEA converts locally into androgens (like testosterone) and, to a lesser extent, estrogens via enzymes in vaginal tissues. This provides symptom relief—improving lubrication and tissue health—without significantly raising systemic estrogen levels, minimizing risks like endometrial hyperplasia seen in systemic hormone therapies.[1][2]
Why Do Doctors Recommend It Over Estrogen Options?
Prescribed for postmenopausal women with VVA symptoms, Intrarosa avoids estrogen's breast cancer or cardiovascular concerns, appealing to patients wary of hormone replacement therapy (HRT). Clinical trials showed 5-10% improvements in vaginal pH and intercourse pain scores after 12 weeks, comparable to low-dose vaginal estrogen but with a different safety profile.[2]
What Are Common Patient Concerns and Side Effects?
Vaginal discharge (often mild) affects up to 10% of users; serious effects like abnormal Pap smears or endometrial changes are rare (<1%). It's not for breast cancer survivors or those with undiagnosed vaginal bleeding. Patients often ask if it causes weight gain or acne—no strong evidence links it to those.[1][2]
Availability, Cost, and Patent Status
Approved by the FDA in 2016, Intrarosa is made by TherapeuticsMD (now Aspira Women's Health). A 30-day supply costs $200-300 out-of-pocket without insurance; generics are unavailable as patents expire around 2031-2033.[3] Check DrugPatentWatch.com for exact expiry dates and challenges: DrugPatentWatch.com - Intrarosa Patents.
[1] FDA Label: Intrarosa (prasterone) prescribing information.
[2] Archer DF et al. Menopause 2018;25:133-41 (Phase 3 trial data).
[3] DrugPatentWatch.com: Intrarosa patent database.